Antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients (pts) with advanced HER2+ (IHC3+) gastric carcinoma (GC)
Catenacci, Daniel V.T., Lim, Kian Huat, Uronis, Hope Elizabeth, Kang, Yoon-Koo, Ng, Matthew C.H., Gold, Philip Jordan, Enzinger, Peter C., Lee, Keun Wook, Lacy, Jill, Park, Se Hoon, Yen, Jennifer, Odegaard, Justin, Franovic, Aleksandra, Baughman, Jan E., Wynter-Horton, Aisha, Chen, Francine, Moore, Paul A., Wu, Tony, Davidson-Moncada, Jan Kenneth, Bang, Yung-Jue
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article
Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T)
Catenacci, Daniel V.T., Park, Haeseong, Uronis, Hope Elizabeth, Kang, Yoon-Koo, Lacy, Jill, Enzinger, Peter C., Park, Se Hoon, Lee, Keun Wook, Ng, Matthew C.H., Gold, Philip Jordan, Yen, Jennifer, Franovic, Aleksandra, Kelly, Ronan Joseph, Wynter-Horton, Aisha, Li, Daner, Muth, John, Baughman, Jan E., Hong, Sam, Davidson-Moncada, Jan Kenneth, Bang, Yung-Jue
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA)
Catenacci, Daniel V.T., Park, Haeseong, Lockhart, A. Craig, Gold, Philip Jordan, Enzinger, Peter C., Nordstrom, Jeffrey L., Hong, Sam, Hochster, Howard S., Kelly, Ronan Joseph, Uronis, Hope Elizabeth, Bendell, Johanna C., Oh, Sang Cheul, Park, Se Hoon, Kim, Yeul Hong, Kang, Yoon-Koo, Lee, Keun-Wook, Ng, Matthew CH, Wigginton, Jon M., Davidson-Moncada, Jan Kenneth, Bang, Yung-Jue
Published in Journal of clinical oncology (01.02.2018)
Published in Journal of clinical oncology (01.02.2018)
Get full text
Journal Article
A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS
Vey, Norbert, Davidson-Moncada, Jan Kenneth, Uy, Geoffrey L., Rizzieri, David, Khoury, Hanna Jean, Foster, Matthew Charles, Godwin, John E., Topp, Max S., Martinelli, Giovanni, Ciceri, Fabio, Carrabba, Matteo Giovanni, Huls, Gerwin A, Wegener, Antje, Tran, Kathy C., Shannon, Michele, Sun, Jichao, Wigginton, Jon M., DiPersio, John F.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer
Catenacci, Daniel V.T., Kim, Sunnie S., Gold, Philip Jordan, Philip, Philip Agop, Enzinger, Peter C., Coffie, Joe, Schmidt, Emmett V., Baldwin, Malcolm, Nordstrom, Jeffrey L., Bonvini, Ezio, Wigginton, Jon M., Hochster, Howard S., Denlinger, Crystal Shereen, Uronis, Hope Elizabeth, Bendell, Johanna C., Kelly, Ronan Joseph, Davidson-Moncada, Jan Kenneth, Lockhart, Albert C.
Published in Journal of clinical oncology (01.02.2017)
Published in Journal of clinical oncology (01.02.2017)
Get full text
Journal Article